Literature DB >> 7543040

Adequacy of mucosal biopsies for evaluation of intestinal cytokine-specific mRNA. Comparative study of RT-PCR in biopsies and isolated cells from normal and inflamed intestine.

K Fukushima1, G West, C Fiocchi.   

Abstract

Endoscopic biopsies are being increasingly utilized to investigate cytokine profiles in normal and diseased intestine. To evaluate the adequacy of mucosal biopsies as a source of cytokine-specific mRNA, we measured their content of interleukin-1 beta (IL-1 beta) and interleukin-2 (IL-2) mRNA by reverse transcription-polymerase chain reaction and compared it to that of autologous lamina propria mononuclear cells in control and inflammatory bowel disease-involved specimens. High-quality total RNA was recovered more consistently from cell isolates than from biopsies. Interleukin-1 beta mRNA was reliably detected in both cell and biopsy samples, whereas IL-2 mRNA was measurable in all lamina propria cells but not always in biopsies. Compared to controls, levels of IL-1 beta were significantly elevated in Crohn's disease and ulcerative colitis cells and biopsies, and a weak but significant correlation existed between values derived from the two sources. In contrast, only ulcerative colitis cell isolates but not biopsies contained significantly reduced concentrations of IL-2 mRNA compared to those of control and Crohn's disease samples, and no correlation was found between cell and biopsy contents. Widely different levels of cytokine-specific mRNA were present in closely adjacent biopsies, particularly for IL-2. These results suggest that mucosal biopsies are suitable to assess some but not all cytokine-specific mRNA due to variation in RNA recovery, intrinsic level of cytokine gene expression, and substantial variability of cytokine transcripts.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7543040     DOI: 10.1007/bf02285198

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  27 in total

1.  Soluble interleukin 2 and CD8 and CD4 receptors in inflammatory bowel disease.

Authors:  T Matsuura; G A West; J S Klein; L Ferraris; C Fiocchi
Journal:  Gastroenterology       Date:  1992-06       Impact factor: 22.682

2.  Intestinal lymphocyte subpopulations in inflammatory bowel disease: an analysis by immunohistological and cell isolation techniques.

Authors:  W S Selby; G Janossy; M Bofill; D P Jewell
Journal:  Gut       Date:  1984-01       Impact factor: 23.059

3.  Human intestinal mononuclear cells. I. Investigation of antibody-dependent, lectin-induced, and spontaneous cell-mediated cytotoxic capabilities.

Authors:  R P MacDermott; G O Franklin; K M Jenkins; I J Kodner; G S Nash; I J Weinrieb
Journal:  Gastroenterology       Date:  1980-01       Impact factor: 22.682

4.  Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis.

Authors:  G E Mullin; A J Lazenby; M L Harris; T M Bayless; S P James
Journal:  Gastroenterology       Date:  1992-05       Impact factor: 22.682

5.  Interleukin 2 activity of human intestinal mucosa mononuclear cells. Decreased levels in inflammatory bowel disease.

Authors:  C Fiocchi; M L Hilfiker; K R Youngman; N C Doerder; J H Finke
Journal:  Gastroenterology       Date:  1984-04       Impact factor: 22.682

6.  Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification.

Authors:  K L Isaacs; R B Sartor; S Haskill
Journal:  Gastroenterology       Date:  1992-11       Impact factor: 22.682

7.  Microscopic activity in ulcerative colitis: what does it mean?

Authors:  S A Riley; V Mani; M J Goodman; S Dutt; M E Herd
Journal:  Gut       Date:  1991-02       Impact factor: 23.059

8.  Immune activation genes in inflammatory bowel disease.

Authors:  T Matsuura; G A West; K R Youngman; J S Klein; C Fiocchi
Journal:  Gastroenterology       Date:  1993-02       Impact factor: 22.682

9.  Role of interleukin 1 in inflammatory bowel disease--enhanced production during active disease.

Authors:  M Ligumsky; P L Simon; F Karmeli; D Rachmilewitz
Journal:  Gut       Date:  1990-06       Impact factor: 23.059

10.  Quantitation of mRNA by the polymerase chain reaction.

Authors:  A M Wang; M V Doyle; D F Mark
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

View more
  6 in total

1.  Cytokine mRNA expression in intestinal tissue of interleukin-2 deficient mice with bowel inflammation.

Authors:  I B Autenrieth; N Bucheler; E Bohn; G Heinze; I Horak
Journal:  Gut       Date:  1997-12       Impact factor: 23.059

2.  Pattern of cytokine and adhesion molecule mRNA in hapten-induced relapsing colon inflammation in the rat.

Authors:  F F Sun; P S Lai; G Yue; K Yin; R G Nagele; D M Tong; R F Krzesicki; J E Chin; P Y Wong
Journal:  Inflammation       Date:  2001-02       Impact factor: 4.092

3.  Preventing effect of anti-ICAM-1 and anti-LFA-1 monoclonal antibodies on murine islet allograft rejection.

Authors:  K Arai; M Sunamura; Y Wada; M Takahashi; M Kobari; K Kato; H Yagita; K Okumura; S Matsuno
Journal:  Int J Pancreatol       Date:  1999-08

4.  An approach to analyze mechanisms of intestinal adaptation following total proctocolectomy.

Authors:  Kouhei Fukushima; Sho Haneda; Yuji Funayama; Kazuhiro Watanabe; Atsushi Kouyama; Ken-Ichi Takahashi; Hitoshi Owaga; Chikashi Shibata; Iwao Sasaki
Journal:  J Gastrointest Surg       Date:  2006-05       Impact factor: 3.452

Review 5.  Mucosal biomarkers in inflammatory bowel disease: key pathogenic players or disease predictors?

Authors:  Franco Scaldaferri; Carmen Correale; Antonio Gasbarrini; Silvio Danese
Journal:  World J Gastroenterol       Date:  2010-06-07       Impact factor: 5.742

6.  Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis.

Authors:  S Melgar; M M-W Yeung; A Bas; G Forsberg; O Suhr; A Oberg; S Hammarstrom; A Danielsson; M-L Hammarstrom
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.